Pulsenmore FY EPS $(0.77), Sales $12.547M
Pulsenmore FY 2025 Sales $12.547M, Up 374% YoY, Net Loss Of $5M Vs. $10M YoY
Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance
Pulsenmore Announces New Commercial Engagement With TLC Perinatal PA As Part Of Its Growing U.S. Rollout
Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center
Pulsenmore Secures First Commercial Agreement With Leading U.S. Medical Center For Home Ultrasound Services Following FDA Approval
Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation
Pulsenmore Signs Commercial Agreement With Clalit To Launch At-Home Follicular Monitoring Service Valued At $4.5M
Pulsenmore to commence trading on Nasdaq
Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S.
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
